APLSApellis Pharmaceuticals, Inc.

$3B

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$14M

Gross Profit

$13M91.3% margin

Operating Income

-$129M-897.0% margin

Net Income

-$139M-966.1% margin

EPS (Diluted)

$-1.42

QoQ Revenue Growth

-76.1%

Cash Flow

Operating Cash Flow

-$112M

Free Cash Flow

-$112M

Stock-Based Comp.

$21M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$684M

Stockholders' Equity

$462M

Cash & Equivalents

$633M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$14M	$0	—
Gross Profit	$13M	-$394,000	+3433.5%
Operating Income	-$129M	-$125M	-3.5%
Net Income	-$139M	-$184M	+24.4%

Revenue Segments

Product

$12M84%

Licensing And Other Revenue

$2M16%

APLS Q1 2022 Earnings — Apellis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena